DeuterOncology is focused on the pre-clinical validation and development of DO-2, a novel MET and RAS pathway inhibitor sublicensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017. DeuterOncology’s portfolio contains a sublicense to the all OCTIMET compounds, includes a clinical-stage MET kinase inhibitor that has been evaluated in both a monotherapy and combination therapy setting in cancer patients in Europe. DeuterOncology works together with a broad established network of collaborators across the world to try to bring new solutions to cancer patients
Member count: 1-10
Total raised: $6.118552M
Founded date: 2020
Investors 1
Date | Name | Website |
- | Newton Bio... | newtonbioc... |
Funding Rounds 1
Date | Series | Amount | Investors | Deal News |
19.01.2023 | Series A | $6.118552M | - | finsmes.co... |
Mentions in press and media 2
Date | Title | Description | Category | Author | Source |
19.01.2023 | DeuterOnco... | DeuterOncology, a Liege, Belgi... | Belgium | - | finsmes.co... |
- | DeuterOnco... | “Home | DeuterOncology NV” | - | - | fastfounde... |